Glioma susceptibility 1

This Phase 3 trial compares the drug niraparib to the standard chemo temozolomide in 450 adults with newly diagnosed, aggressive glioblastoma that has a specific genetic marker (MGMT unmethylated). Participants take the assigned drug daily during radiation, then continue until th…

This study tests whether giving a higher radiation dose to a brain area called the subventricular zone (where stem cells live) can delay glioblastoma from coming back. About 60 adults with newly diagnosed glioblastoma will receive standard radiation and chemo, but half will get e…

This trial tests a combination of donor immune cells (targeting a common virus) and the drug pembrolizumab (Keytruda) in 58 people with glioblastoma, an aggressive brain cancer. The goal is to see if this approach can shrink tumors and help patients live longer. The study has two…

This early-stage trial is testing an experimental drug called APX005M in 32 children with brain tumors that have come back or are hard to treat, including a type of brain stem glioma. The drug works by activating the immune system to attack cancer cells. The main goals are to fin…

This early-stage study tested the safety and best dose of vorinostat when given with the chemotherapy drug temozolomide in 83 adults with aggressive brain tumors called malignant gliomas. The goal was to see if adding vorinostat could make the tumor cells more sensitive to chemot…

This study planned to test a new treatment combining CYNK-001 (natural killer cells from donated cord blood) with interleukin-2 in adults whose glioblastoma had returned and could be surgically removed. The goal was to see if this combination was safe and could extend the time be…

This early-phase study tests a vaccine called SurVaxM in 35 children with certain brain tumors that have come back or are hard to treat. The vaccine is designed to teach the immune system to find and destroy tumor cells that have a protein called survivin. The goal is to see if i…

This early-phase study tests whether adding a drug called S-Gboxin to standard treatment can help people with glioblastoma, a fast-growing brain cancer. The drug works by cutting off the energy supply to cancer cells. Ten patients with recurrent or progressive disease will receiv…

This study tests a technique that delivers two cancer drugs, bevacizumab and carboplatin, directly into the brain's arteries for people with recurrent glioblastoma or anaplastic astrocytoma. The goal is to see if this method is safe and can slow tumor growth better than standard …

This early-stage trial tests a new surgical approach for recurrent glioblastoma, an aggressive brain cancer. After standard tumor removal, surgeons place a piece of abdominal tissue (omentum) into the brain cavity to bypass the blood-brain barrier. The study involves 10 adults an…

This early-stage trial tested a personalized DNA vaccine designed to train the immune system to attack glioblastoma, a fast-growing brain cancer. Nine patients with a specific type of glioblastoma (unmethylated MGMT) received the vaccine along with an immune booster. The main goa…

This study tests whether adding the targeted drug pazopanib to standard chemotherapy (temozolomide) can safely control glioblastoma, an aggressive brain cancer. About 51 adults who had surgery and chemoradiation will receive the combination. The main goal is to find the best dose…

This early-phase study tests a new treatment for glioblastoma, an aggressive brain cancer. The approach uses a patient's own immune cells, modified in the lab to better recognize and attack the tumor, combined with chemotherapy. The main goal is to check the safety of this therap…

This early-stage trial tests whether combining a precise form of radiation (stereotactic radiosurgery) with two immunotherapy drugs (MBG453 and spartalizumab) is safe for people whose glioblastoma has come back. The study includes 16 adults with recurrent GBM. The main goal is to…

This trial tests an implantable ultrasound device that temporarily opens the blood-brain barrier, allowing chemotherapy to reach brain tumors. It includes 57 adults with recurrent glioblastoma who have already tried 1-2 treatments. The goal is to find a safe dose and see if this …

This phase II study tests a vaccine called SurVaxM, designed to train the immune system to attack glioblastoma cells, when given alongside standard chemotherapy (temozolomide). The trial includes 66 patients with newly diagnosed, survivin-positive glioblastoma or gliosarcoma. The…

This study tests a drug called ACP-196 (acalabrutinib) in 24 adults with recurrent glioblastoma, an aggressive brain cancer that has returned after standard treatment. Participants take the drug by mouth once or twice daily. The main goal is to see if the drug can shrink tumors o…

This early-phase trial tests whether adding the drug AZD1390 to standard radiation therapy can help people with a fast-growing brain tumor called glioblastoma (grade 4 glioma). The study includes both newly diagnosed and recurrent patients. First, researchers measure how much dru…

This early-phase trial tests the drug niraparib (Zejula) in people with two types of brain cancer: newly diagnosed glioblastoma and recurrent glioma with specific genetic changes (IDH mutation and ATRX loss). The study first checks if the drug reaches the tumor tissue, then gives…

This trial tests whether the drug ribociclib can reach brain tumors in people with recurrent high-grade glioma or meningioma. About 48 participants take the drug before their scheduled tumor-removal surgery. The goal is to measure how much drug gets into the tumor and surrounding…

This early-stage study tests a genetically engineered virus (rQNestin34.5v.2) that is injected directly into recurrent brain tumors to see if it is safe and what dose works best. About 62 adults with certain types of brain cancer that have come back or worsened are taking part. T…

This early-phase trial is testing whether giving two immune-boosting drugs (nivolumab and ipilimumab) before surgery can help fight recurrent glioblastoma, a fast-growing brain cancer. About 63 adults whose tumor has returned after standard treatment will receive the drugs or a p…

This study aimed to test an experimental virus therapy called G207, combined with a single dose of radiation, in children whose high-grade glioma had come back after prior treatment. The virus was injected directly into the brain tumor to kill cancer cells and trigger an immune r…

This study tests an experimental drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The trial includes cancers like glioblastoma, melanoma, breast, and prostate cancer. It aims to find a safe dose and see if the drug can shrin…

This pilot study tests whether an energy-restricted ketogenic diet (ERKD) can help control glioblastoma, an aggressive brain cancer. Sixteen adults with newly diagnosed glioblastoma will follow the diet while receiving standard radiation and chemotherapy. The goal is to see if th…

This study tests a two-year follow-up program for 200 adults with hereditary cancer syndromes like BRCA or Lynch syndrome. Participants get personalized care plans and regular check-ins with a genetics doctor to help them follow cancer prevention and screening guidelines. The goa…

This study tests whether adding the experimental drug BPM31510 (with vitamin K1) to standard radiation and chemotherapy can help people with newly diagnosed glioblastoma live longer without their cancer growing. About 50 adults with this aggressive brain tumor will receive the co…

This early-phase study tests whether a new type of cell therapy, made from a patient's own immune cells that are genetically modified to resist chemotherapy, can be safely given alongside standard chemotherapy for newly diagnosed glioblastoma. About 22 adults with this aggressive…

This phase 2 study tests whether adding the antiviral drug valganciclovir to standard treatment (radiation and chemotherapy) can help people with glioblastoma live longer. The idea is that many glioblastomas carry a virus called CMV, which may make the cancer more aggressive. Abo…

This study tests whether adding high-dose vitamin C to the usual treatment (radiation and chemotherapy) helps adults with a newly diagnosed aggressive brain tumor called glioblastoma. About 90 participants will receive the vitamin C infusions alongside standard care. The goal is …

This early-stage study tests whether adding an experimental drug called OKN-007 to standard chemoradiotherapy is safe and tolerable for people with newly diagnosed glioblastoma, a fast-growing brain cancer. About 27 participants will receive the combination after surgery. The mai…

This early-phase trial tests whether adding high-dose vitamin C and an iron supplement (ferumoxytol) to standard radiation and chemotherapy can help adults with newly diagnosed glioblastoma, an aggressive brain tumor. The study includes 17 participants and focuses on finding a sa…

This early-phase trial tests whether a drug called rhIL-7-hyFc can safely increase lymphocyte counts in people with high-grade glioma who have low immune cells after standard radiation and chemotherapy. About 42 participants will receive either the drug or a placebo by injection.…

This study tests whether adding the experimental drug LAM561 to standard radiation and chemotherapy can help people with newly diagnosed glioblastoma, a fast-growing brain tumor. About 144 adults aged 18 to 75 will receive either LAM561 or a placebo alongside their usual treatmen…

This study tests a combination of two drugs, cobolimab and dostarlimab, in children and young adults (up to age 21) with advanced solid tumors that have not responded to other treatments. The goal is to find the safest dose and see if the combination can shrink tumors. The study …

This phase 3 trial tests whether giving a dose of radiation directly to the tumor site during surgery (intraoperative radiotherapy) can help people with a newly diagnosed aggressive brain cancer called glioblastoma live longer without their cancer growing. The study involves 314 …

This study tests whether adding an experimental drug called NanO2 to standard radiation and chemotherapy can help people with newly diagnosed glioblastoma, an aggressive brain cancer. NanO2 is designed to deliver more oxygen to tumors, which may make radiation work better. About …

This early-stage trial tests a single dose of M032, a genetically modified herpes simplex virus that produces IL-12, in 29 patients with recurrent or progressive brain tumors (glioblastoma, anaplastic astrocytoma, or gliosarcoma). The virus is infused directly into the tumor area…

This early-phase study tests an oral drug called DSP-0390 in 39 adults whose high-grade glioma (a fast-growing brain tumor) has come back after prior treatment. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants must b…

This study is developing a blood test to find early-stage tumors in people with hereditary cancer syndromes (high genetic risk for cancer). Researchers will collect blood samples and medical data from about 1,400 participants across Canada. They will also interview patients and d…

This study explores whether a supervised, circuit-based resistance training program can help glioblastoma patients maintain muscle mass and perform daily tasks more easily. Researchers will enroll 24 adults with glioblastoma who are currently on treatment. Participants will exerc…

This study tests whether using a virtual reality headset during PICC line placement can reduce anxiety and pain in cancer patients. About 120 adults will be randomly assigned to either receive VR plus standard care or standard care alone. The goal is to see if this non-drug appro…

This Phase 2 trial tests whether dichloroacetate (DCA), a drug that affects cell energy use, can alter tumor metabolism in people with recurrent glioblastoma. Forty patients scheduled for surgery will either receive DCA or no drug for one week before their operation. Researchers …

This pilot study aimed to see if a diet low in two specific nutrients (cysteine and methionine) could affect metabolism in patients with recurrent gliomas. Up to 30 participants were to be randomly assigned to either a normal diet or the special diet for 2, 4, or 7 days before st…

This study is creating a web-based program to help people with hereditary cancer mutations share their genetic test results with family members. The goal is to increase awareness among at-risk relatives so they can take steps to prevent cancer. The program is designed for patient…

This study looks at whether short educational videos can help people with inherited cancer gene mutations learn more about their condition. About 43 adults who carry mutations in genes like BRCA1 or BRCA2 will watch the videos and then take a quiz. The goal is to see if this simp…

This study tests two simple, scalable methods to help people with inherited cancer risk follow through on recommended screenings. Researchers will provide online educational resources and personalized phone outreach to 900 participants. The goal is to see if these approaches impr…

This study is testing a chatbot and online portal called AYA-RISE to help adolescents and young adults (ages 12-24) who have genetic conditions that raise their cancer risk. The goal is to see if the tool helps them communicate with family and doctors and make informed decisions …

This study looks at the complete DNA and RNA of 10 people and their families who are at high risk for hereditary cancer but have no known genetic cause. Researchers will use whole genome sequencing and tumor analysis to discover new genetic changes that may lead to cancer. The go…

The IMPACT Study is testing two online tools—GeneSHARE and LivingLabReport—to help people with inherited cancer gene variants share their results with family members and follow cancer screening guidelines. The study involves 720 adults who have a genetic variant linked to cancers…

This study aimed to see if a rapid whole genome sequencing test on amniotic fluid could give faster genetic diagnoses for fetuses with suspected genetic diseases. Researchers planned to compare results from amniotic fluid and blood samples from up to 90 families. However, the stu…